Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014 Oct;32(10):1005-13.
Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I. Cost-effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Clemens A, Abeysinghe S, Gonschior A-K, Hosel V, Lock S, Wolowacz SE, Woods M, Zimovetz E. Comparative efficacy and safety of dabigatran etexilate and rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism. Poster presented at the 55th ASH Annual Meeting; 2013. [abstract] Blood. 2013 Nov 15; 122(21):4807. doi: 10.1182/blood.V122.21.4807.4807
Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Link BK. PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: report from the National LymphoCare Study. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):4245. doi: 10.1182/blood.V122.21.4245.4245
Nabhan C, Byrtek M, Dawson KL, Zhou X, Link BK, Friedberg JW. A proposed prognostic model for overall survival in the oldest old (>80 years old) follicular lymphoma patients. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):3058. doi: 10.1182/blood.V122.21.3058.3058
Casulo C, Byrtek M, Dawson K, Zhou X, Farber CM, Flowers CR. Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the National LymphoCare Study. Presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2013. New Orleans, LA. [abstract] Blood. 2013 Nov; 122(21):510. doi: 10.1182/blood.V122.21.510.510
Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.
Davis KL, Price GL, Karve SJ, Pohl G, Walgren RA. Comorbidity burden in elderly persons with non-cml myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):1734. doi: 10.1182/blood.V120.21.1734.1734
Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. Clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia: evidence from U.S. hospitals, 2007-2010. Presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):239. doi: 10.1182/blood.V120.21.239.239
Martin P, Link BK, Byrtek M, Dawson K, Ziemiecki RM, Friedberg J. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 8, 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):3702. doi: 10.1182/blood.V120.21.3702.3702
Karve SJ, Price GL, Davis KL, Pohl G, Walgren RA. Health care utilization and associated costs in elderly persons with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):4273. doi: 10.1182/blood.V120.21.4273.4273
Price GL, Davis KL, Karve SJ, Pohl G, Walgren RA. Survival patterns in elderly patients with myeloproliferative neoplasms: real-world evidence from a United States Medicare population. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):428. doi: 10.1182/blood.V120.21.428.428
Mauskopf J, Brodan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2012 Oct;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Treatment response patterns and related prognostic indicators in chronic myeloid leukemia patients: a multi-country medical record review study. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3131. doi: 10.1182/blood.V118.21.3131.3131
Zhou X, Wang J, Zhang J, Copley-Merriman K, Torigoe Y, Reyes C. Symptoms and toxicity of rituximab maintenance (R-M) versus observation (OBS) following rituximab plus chemotherapy in patients with follicular lymphoma. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3661. doi: 10.1182/blood.V118.21.3661.3661
Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775
Henk HJ, Deeter R, Kaye JA, Becker LK, Legg JC, Rothman KJ. Effect of age on neutropenia-related hospitalization in Non-Hodgkin's lymphoma patients receiving myelosuppressive chemotherapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):2082. doi: 10.1182/blood.V118.21.2082.2082
Kiladjian J, Al-Ali H, Gisslinger H, Knoops L, Waltzman RJ, Mendelson E, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):795. doi: 10.1182/blood.V118.21.795.795
Meyers JL, Yu YF, Davis KL. Medicare fee-for-service enrollees with acute myelogenous leukemia: an analysis of treatment patterns and patient survival. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):505. doi: 10.1182/blood.V118.21.505.505
Mangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research. 2011 Feb 1;4(1):9-12.
Nastoupil L, Sinha R, Byrtek M, Taylor M, Cerhan JR, Friedberg J, Ziemiecki RM. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Jan; 118(21):97. doi: 10.1182/blood.V118.21.97.97
Talbird SE, Mauskopf J, Smets E, Brogan AJ. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):129-46.
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.
Candrilli SD, O'Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Poster presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5, 2009. New Orleans, LA. [abstract] Blood. 2009 Nov 20; 114(22):2483. doi: 10.1182/blood.V114.22.2483.2483
Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics. 2007 Oct 1;25(10):863-79.
Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.
Bann CM, Fehnel S, Gagnon DD. Development and validation of the diabetic foot ulcer scale-short form (DFS-SF). Pharmacoeconomics. 2003 Jan 1;21(17):1277-90.
Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.
McLeod LD, Fehnel SE, Brandman J, Symonds T. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomics. 2003 Jan 1;21(15):1069-79.
Bell T, Candrilli S, Irish W, Morris E, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. Blood. 2002 Jan 1;100(11):221A.
Poole WK, Pollack M, Rapoport I, Williams V, Koch MA, Rao AV, Bartel DA. Use of Multivariate Methods in Quantifying the Variability in the Perception of Neonatal Intensive Care Unit Characteristics in Nine Hospitals in the Washington, DC Area: the NIH-DC Initiative to Reduce Infant Mortality in Minority Populations in the District of Columbia. Interstat. 2002 Jan 1.
Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost-effectiveness of zanamivir for the treatment of influenza in a high-risk population in Australia. Pharmacoeconomics. 2000 Jun;17(6):611-20. doi: 10.2165/00019053-200017060-00007.
Sculpher M, Palmer MK, Heyes AE. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Pharmacoeconomics. 2000 Apr;17(4):361-70.
McKenna SP, Doward LC. A review of quality of life in Alzheimer's disease. Parts 1 and 2: issues in assessing disease impact and drug effects. Pharmacoeconomics. 1999 Oct;16(4):417-9.
Whalley D, McKenna SP. Measuring quality of life in patients with depression or anxiety. Pharmacoeconomics. 1995 Oct;8(4):305-15.
McKenna SP, Doward LC. Quality-of-life assessment of adults with growth hormone deficiency: implications for drug therapy. Pharmacoeconomics. 1994 Nov 1;6(5):434-41.
Kaufman DW, Kelly JP, Johannes CB, Sandler A, Harmon D, Stolley PD, Shapiro S. Acute thrombocytopenic purpura in relation to the use of drugs. Blood. 1993 Nov 1;82(9):2714-8.